Accustem Sciences Files Q2 2024 10-Q

TL;DR

Accustem Sciences filed its Q2 10-Q, check financials for latest performance.

AI Summary

Accustem Sciences Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware and operating in Pharmaceutical Preparations, reported financial data for the second quarter and the first six months of 2024. Key financial figures and balance sheet information as of various dates in 2023 and 2024 are included in the filing.

Why It Matters

This filing provides investors with the latest financial performance and position of Accustem Sciences Inc., crucial for understanding the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical preparations company, Accustem Sciences is subject to regulatory risks, market competition, and R&D uncertainties.

Key Numbers

• 2024-06-30 — Period End Date (The end of the fiscal quarter for which the report is filed.)
• 2024-09-16 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 2023-12-31 — Previous Fiscal Year End (Provides a comparison point for financial performance and position.)

Key Players & Entities

• Accustem Sciences Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240916 (date) — Filing date
• 5 PENN PLAZA, 19TH FLOOR #1954 (address) — Company's business and mailing address
• DE (state) — State of incorporation
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $1.076247 — m EUROS to USD using exchange rate of 1:$1.076247 ) 50,000 ($ 53,812 ) within 30 days

Filing Documents

• form10-q.htm (10-Q) — 815KB
• ex31-1.htm (EX-31.1) — 15KB
• ex31-2.htm (EX-31.2) — 14KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-24-036330.txt ( ) — 4086KB
• acut-20240630.xsd (EX-101.SCH) — 23KB
• acut-20240630_cal.xml (EX-101.CAL) — 32KB
• acut-20240630_def.xml (EX-101.DEF) — 95KB
• acut-20240630_lab.xml (EX-101.LAB) — 228KB
• acut-20240630_pre.xml (EX-101.PRE) — 175KB
• form10-q_htm.xml (XML) — 732KB

SIGNATURES

SIGNATURES 22 i PART I - FINANCIAL INFORMATION Item 1. Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information which are the accounting principles that are generally accepted in the United States of America and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations and cash flows of the Company for the interim periods presented. The results for the period ended June 30, 2024 are not necessarily indicative of the results of operations for the full year. These financial audited consolidated financial statements for the fiscal years December 31, 2023 and 2022 included in our annual report on Form 10-K filed with the US. Securities and Exchange Commission (the "SEC") on March 22, 2024. ACCUSTEM SCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED) June 30, 2024 December 31, 2023 ASSETS Current Assets Cash $ 46,072 $ 21,481 Prepaid expenses 91,355 108,368 Other Current Assets - Total Current Assets 137,427 129,849 Equipment, net 2,233 4,048 TOTAL ASSETS $ 139,660 $ 133,897 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable $ 744,693 $ 578,378 Related party payable 2,043,158 1,454,986 Accrued expenses 154,898 156,434 Note Payable 81,217 55,679 Total Current Liabilities 3,023,966 2,245,477 TOTA

View Full Filing

View this 10-Q filing on SEC EDGAR